Friday, 25 October 2013

Phase 3-LY2439821 (ixekizumab) for psoriasis and psoriatic arthritis. « New Drug Approvals

Phase 3-LY2439821 (ixekizumab) for psoriasis and psoriatic arthritis. « New Drug Approvals:

'via Blog this'

No comments:

Post a Comment